Compare
EoCene Ltd. vs Genelux Corp vs Marker Therapeutics, Inc. vs Lftd Partners Inc.
| Latest fiscal year | EoCene Ltd. EOCN | Genelux Corp GNLX | Marker Therapeutics, Inc. MRKR | Lftd Partners Inc. LIFD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $8.0K | $3.55M | $36.92M |
| Revenue growth (YoY) | n/a | 0.0% | -46.2% | -1.1% |
| Gross margin | n/a | n/a | n/a | 34.2% |
| Operating margin | n/a | n/m | -363.5% | 2.5% |
| Net margin | n/a | n/m | -343.0% | -67.3% |
| Net income | $6.90M | -$32.15M | -$12.16M | -$24.86M |
| EPS (Diluted) | $2.39 | -$0.86 | -$0.79 | -$1.68 |
| Operating cash flow | -$6.32M | -$25.27M | -$12.01M | $1.32M |
| Free cash flow | n/a | -$26.37M | n/a | $1.20M |
| Cash & equivalents | $3.98M | $5.33M | $16.07M | $1.77M |
| Total assets | $18.63M | $19.03M | $19.07M | $19.27M |
| Total liabilities | n/a | $7.48M | $2.27M | $6.64M |
| Shareholders' equity | $15.78M | $11.54M | $16.80M | $12.63M |
| Return on year-end equity | 43.7% | -278.5% | -72.4% | -196.8% |
| Shares outstanding | 6.58M | 38.14M | 16.70M | 14.82M |
Revenue, most recent five fiscal years
| Fiscal year | EoCene Ltd. | Genelux Corp | Marker Therapeutics, Inc. | Lftd Partners Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $8.0K Ended 2025-12-31 | $3.55M Ended 2025-12-31 | $36.92M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $8.0K Ended 2024-12-31 | $6.59M Ended 2024-12-31 | $37.33M Ended 2024-12-31 |
| 2 years earlier | $2.04M Ended 2018-12-31 | $170.0K Ended 2023-12-31 | $3.31M Ended 2023-12-31 | $51.61M Ended 2023-12-31 |
| 3 years earlier | $1.08M Ended 2017-12-31 | $11.07M Ended 2022-12-31 | $3.51M Ended 2022-12-31 | $57.42M Ended 2022-12-31 |
| 4 years earlier | $467.0K Ended 2016-12-31 | n/a | $1.24M Ended 2021-12-31 | $31.66M Ended 2021-12-31 |